Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-17
2011-11-22
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S299000, C546S112000, C546S152000
Reexamination Certificate
active
08063066
ABSTRACT:
Compounds are provided for use with MEK that comprise:wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
REFERENCES:
patent: 2008/0255160 (2008-10-01), Dong et al.
patent: 1319656 (2003-06-01), None
patent: WO 9410163 (1994-05-01), None
patent: WO 2004056781 (2004-07-01), None
patent: WO 2005/051300 (2005-06-01), None
patent: WO 2005/051302 (2005-06-01), None
patent: WO 2005/121142 (2005-12-01), None
patent: WO 2008/079814 (2008-07-01), None
Yamaguchi et al. “Identification of JTP-70902, a p15ink4—inductive compound as a novel MEK1/2 inhibitor” Cancer Sci, Nov. 2007, vol. 98, No. 11 p. 1809-186.
Ohren, et al. “Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition” Nature Structural & molecular biology, Dec. 2004, vol. 11, No. 12, p. 1192-8.
Price, “Putative allosteric MEK1 and MEK2 inhibitor” Expert. Opin. (2008) 18(6);603-27.
Tominaga et al. “Synthesis of Pyrimide Derivatives Using N-Bis(methylthio)methylenecyanamide” J. of Heterocyclic Chem., 1991. vol. 28, p. 1039.
Wallace et al. “Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy” Current Topics in Medicinal Chemistry, 2005, vol. 5, p. 215-229. XP008069118.
Dong Qing
Kanounl Toufiko
Wallace Michael B.
Brustein Mitchell R.
Stemerick David M.
Takeda Pharmaceutical Company Limited
Ward Paul V.
LandOfFree
MAPK/ERK kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MAPK/ERK kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAPK/ERK kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282343